Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

Description

The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKnife system is a new type of radiation machine that uses a special system to precisely focus large doses of x-rays on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time.

Conditions

Prostate Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKnife system is a new type of radiation machine that uses a special system to precisely focus large doses of x-rays on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with your condition and to evaluate the effect of this treatment on your quality of life over time.

Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Fountain Valley

Orange Coast Memorial Medical Center, Fountain Valley, California, United States, 92708

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histologically proven prostate adenocarcinoma
  • 2. Biopsy within 12 months of date of registration
  • 3. Clinical Stage I-IV, MX-M0 (AJCC 6th Edition) M-stage determined by physical exam, CT, MRI, or Bone Scan. Bone scan not required for Monotherapy Risk Group patients unless clinical findings suggest possible osseous metastases. Bone Scan and contrast CT of the abdomen should be done patients in the Boost Risk Group patients.
  • 4. Prostate volume: ≤ 100 cc (recommended not required) Determined using: volume = π/6 x length x height x width Measurement from CT or ultrasound ≤90 days prior to registration.
  • 5. ECOG performance status 0-1
  • 6. No prior prostatectomy or cryotherapy of the prostate
  • 7. No prior radiotherapy to the prostate or lower pelvis
  • 8. No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.
  • 9. Completion of patient questionnaires
  • 10. Consent signed

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

MemorialCare Health System,

Asif Harsolia, MD, PRINCIPAL_INVESTIGATOR, MemorialCare

Study Record Dates

2029-06